Cisplatin PopPK Simulator
Indication: Cancer chemotherapy
Interactive population PK simulator for cisplatin, a platinum chemotherapy agent used across multiple solid tumors. Models IV pharmacokinetics with renal function effects to support exposure-aware dosing.
Drug Overview
Clinical Context
- Molecular Target
- DNA crosslinking through platinum-DNA adduct formation
- Drug Class
- Platinum
- Therapeutic Area
- Oncology
- Indication
- Cancer chemotherapy
- Route of Administration
- IV
Model Information
- Model Type
- popPK
This simulator was built from published pharmacometric literature using PKPDBuilder's AI-powered model extraction pipeline.
About This Simulator
This interactive pharmacokinetic simulator for Cisplatin allows you to explore concentration-time profiles under different dosing scenarios. The underlying popPK model characterizes the pharmacokinetics of this platinum following iv administration.
Use the simulator to visualize key exposure metrics including AUC (area under the curve), Cmax (peak concentration), and Ctrough (trough concentration).
Built with PKPDBuilder — an AI-powered platform that transforms published pharmacometric literature into interactive, deployable Shiny applications. No coding required.
Frequently Asked Questions
What is the Cisplatin PK simulator?
This is a free, interactive pharmacokinetic simulator for Cisplatin used in Cancer chemotherapy. It allows researchers, pharmacologists, and students to explore concentration-time profiles, dosing regimens, and exposure metrics based on published population PK models.
What drug class does Cisplatin belong to?
Cisplatin is classified as a Platinum that targets DNA crosslinking through platinum-DNA adduct formation. It is used in the Oncology therapeutic area.
What route of administration does this model simulate?
This simulator models IV administration of Cisplatin. The pharmacokinetic parameters (absorption rate, bioavailability, volume of distribution) are specific to this route.
What type of PK model is used?
This simulator uses a popPK model. Population PK models account for interindividual variability and covariate effects on drug exposure.
Is this simulator free to use?
Yes, all PKPDBuilder simulators are completely free. They are built from published pharmacokinetic literature and are intended for research and educational purposes. No login is required to run simulations.
Can I use this for clinical dosing decisions?
No. This simulator is for research and educational purposes only. It should not be used for clinical decision-making or patient dosing. Always consult the prescribing information and clinical pharmacology guidelines for therapeutic drug use.
Related Simulators
G-CSF Effects in Carboplatin-Treated Cancer Patients
Chemotherapy-induced neutropenia
Methotrexate population PK in Mexican pediatric ALL
Acute lymphoblastic leukemia in pediatric patients receiving high-dose methotrexate
Population PKPD
Unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC), HR+/HER2-negative metastatic breast cancer after endocrine and CDK4/6 inhibitor therapy, and locally advanced or metastatic urothelial cancer
Tamoxifen
Hormone receptor-positive breast cancer adjuvant therapy
Pertuzumab
HER2-positive solid tumors
Serplulimab (HLX10) Population PK Simulator
Extensive-Stage Small Cell Lung Cancer (ES-SCLC)
Ready to Simulate?
Launch the Cisplatin simulator to explore dosing scenarios and pharmacokinetic profiles interactively.
🚀 Launch SimulatorComments
⚠️ Disclaimer
This simulator is for research and educational purposes only. It is not intended for clinical decision-making, patient dosing, or therapeutic drug monitoring. Pharmacokinetic parameters are derived from published literature and represent population-level estimates. Individual patient pharmacokinetics may differ significantly. Always consult approved prescribing information and qualified healthcare professionals for clinical decisions.
Powered by PKPDBuilder.com • Free pharmacokinetic simulators for the scientific community